Eighty-seven (87) percent of Aetna Medicare Advantage members in 4-star plans or higher for 2024
WOONSOCKET, R.I., Oct. 13, 2023 /PRNewswire/ -- Aetna®, a CVS Health® company (NYSE: CVS), announced today that 87 percent of its Medicare Advantage (MA) members are in 2024 Medicare Advantage Prescription Drug (MAPD) plans that are rated 4 stars or higher (out of 5 stars) by the Centers for Medicare & Medicaid Services (CMS). This represents a significant achievement, given the considerably more stringent CMS measurement criteria this year.
- WOONSOCKET, R.I., Oct. 13, 2023 /PRNewswire/ -- Aetna®, a CVS Health® company (NYSE: CVS), announced today that 87 percent of its Medicare Advantage (MA) members are in 2024 Medicare Advantage Prescription Drug (MAPD) plans that are rated 4 stars or higher (out of 5 stars) by the Centers for Medicare & Medicaid Services (CMS).
- "We are committed to delivering outstanding experiences and driving improved health outcomes for our Medicare Advantage members," said CVS Health President and CEO Karen S. Lynch.
- "Our strong 2024 Star Ratings for Aetna are a result of focused execution and seamless collaboration across our entire company.
- Visit AetnaMedicare.com to learn more about the 2024 Aetna Medicare plans.